We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

02 Jun 2026 - 04 Jun 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Antibiotic Effective for Multidrug-Resistant TB

By HospiMedica staff writers
Posted on 23 Jun 2003
A new antibiotic has proven to be effective for treating patients with multi-drug resistant tuberculosis (TB), which is resistant to nearly all currently available TB treatments. More...
The findings were presented at an international conference of the American Thoracic Society in Seattle (WA, USA).

The drug, linezolid (Zyvox), is a new class of antibiotics approved to treat certain strains of bacteria resistant to standard antibiotics such as penicillin, methicillin, and vancomycin but not drug-resistant TB. Doctors decided to try linezolid when all other therapies failed to improve the health of five patients in Bellevue Hospital (New York, NY, USA) The patients took the drug twice a day in pill form for nine to 33 months. Four patients also received interferon gamma three times a week. Following treatment, there was no sign of the TB microbe in sputum from the patients' lungs. Treatment was not associated with many severe side effects.

"Trying the linezolid was a real act of desperation,” said Timothy Harkin, M.D., assistant professor of medicine at New York University School of Medicine and assistant director of Chest Service at Bellevue.” This certainly seems like a promising medication for multidrug-resistnat TB, and there is a continuing need for new antibiotics for this disease.”

The doctors said that further studies are needed to confirm their case reports and they hope the drug will be tested in large clinical trials sponsored by the World Health Organization (WHO). Currently, no new drugs for treating multidrug resistant TB are in clinical trials.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Multi-Chamber Washer-Disinfector
WD 390
New
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The Elyra TFL System uses thulium fiber laser technology for efficient stone dusting and reduced stone migration, with an air-cooled design for quieter, more compact operation (photo courtesy of BD

BD Launches Elyra Laser Platform for Kidney Stone and Soft Tissue Procedures

BD (Becton, Dickinson and Company) has introduced the Elyra Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete its kidney stone care portfolio for urology teams.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.